Only FDA-approved post-surgery nausea drug shifts to new owner - Stock Titan
2026-01-14 • Google News
EGRX
USundefined 00%
Price Chart
Key Statistics
Market Cap
₹ 0
P/E Ratio
0.00
Revenue (TTM)
₹ 0
Volume
0
52W High
₹ 0.00
52W Low
₹ 0.00
Dividend Yield
0.00%
Beta
0.00
Technicals
50-Day MA
N/A
200-Day MA
N/A
52 Week High
N/A
52 Week Low
N/A
About EGRX
No description available.
Employees
N/A
Headquarters
N/A
CEO
N/A